THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
At present, there is more and more evidence in rheumatology on the factors influencing the efficacy of biological agents (BAs), and there is no generally accepted algorithm for managing patients resistant to standard therapy. The paper describes three patients with ankylosing spondylitis (AS) who we...
Saved in:
Main Authors: | D. G. Rumyantseva, M. V. Podryadnova, O. A. Rumyantseva, M. M. Urumova, Sh. Erdes |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2020-04-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2882 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ILIOCAVAL THROMBOSIS WITH A PROXIMAL BORDER TO THE SUPRARENAL SEGMENT OF THE INFERIOR VENA CAVA IN A FEMALE PATIENT WITH ANKYLOSING SPONDYLITIS AND ULCERATIVE COLITIS
by: D. G. Rumyantseva, et al.
Published: (2020-06-01) -
PROGRESSION OF AORTIC AND VALVULAR HEART DISEASES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: A. A. Godzenko, et al.
Published: (2017-10-01) -
The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01) -
COURSE OF UVEITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: A. A. Godzenko, et al.
Published: (2016-09-01) -
Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2022-12-01)